Adeline Crinier

Adeline Crinier

Auto-generated profile, based on publicly available information

Adeline Crinier

Aix Marseille Université, INSERM, CNRS, Centre d'Immunologie de Marseille-Luminy, Marseille, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Immunity
Verified
Journal Article
Open access
ACAdeline Crinier
Adeline Crinier
PMPierre Milpied
Pierre Milpied
BEBertrand Escalière
Bertrand Escalière
CPChristelle Piperoglou
Christelle Piperoglou
JGJustine Galluso
Justine Galluso
ÉVÉric Vivier
Éric Vivier
Natural killer (NK) cells are innate lymphoid cells (ILCs) involved in antimicrobial and antitumoral responses. Several NK cell subsets have been reported in humans and mice, but their heterogeneity across organs and species remains poorly characterized. We assessed the diversity of human and mouse NK cells by single-cell RNA sequencing on thousands of individual cells isolated from spleen and blood. Unbiased transcriptional clustering revealed two distinct signatures differentiating between splenic and blood NK cells. This analysis at single-cell resolution identified three subpopulations in mouse spleen and four in human spleen, and two subsets each in mouse and human blood. A comparison of transcriptomic profiles within and between species highlighted the similarity of the two major subsets, NK1 and NK2, across organs and species. This unbiased approach provides insight into the biology of NK cells and establishes a rationale for the translation of mouse studies to human physiology and disease.

14 August 2017 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
MEMikaël Ebbo
Mikaël Ebbo
ACAdeline Crinier
Adeline Crinier
FVFrédéric Vély
Frédéric Vély
EVEric Vivier
Eric Vivier

25 March 2019 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
GHGuillaume Habif
Guillaume Habif
ACAdeline Crinier
Adeline Crinier
PAPascale André
Pascale André
EVEric Vivier
Eric Vivier
ENEmilie Narni-Mancinelli
Emilie Narni-Mancinelli

1 February 2019 in Seminars in Immunology
Verified
Journal Article
Open access
ACAdeline Crinier
Adeline Crinier
EVEric Vivier
Eric Vivier
MBMathieu Bléry
Mathieu Bléry
Immunotherapies have revolutionized cancer treatment over the last 20 years. They aim either to boost immune cell activation or decrease immune cell inhibition, to improve control over cancer development. Various strategies for improving tumor immunity have been tested. Some have been approved and others are currently in clinical trials. They target the immune system itself, the tumor cells or the microenvironment. Most focus on enhancing T-cell responses, notably through infusions of activating cytokines, the adoptive transfer of activated or engineered T cells, or immune checkpoint inhibitors. ILCs have also emerged as an interesting target for immunotherapy, initially due to the anti-tumor activities of cytotoxic NK cells. However, the other helper-like ILCs can also infiltrate the tumor microenvironment, having either pro- or anti-tumor effects, depending on their phenotype and the type of cancer. Moreover, given the similarities between helper ILCs and T cells in terms of their cytokine profiles and the surface markers they express, immunotherapies targeting T cells may also target helper-like ILCs. We provide here an overview of the field, summarizing the evidence for a role of helper-like ILCs and ways of targeting these cells in solid tumors and hematological malignancies.

1 May 2017 in médecine/sciences
Verified
Journal Article
Closed access
PDF file
ACAdeline Crinier
Adeline Crinier
CVCharlotte Viant
Charlotte Viant
MGMathilde Girard-Madoux
Mathilde Girard-Madoux
ÉVÉric Vivier
Éric Vivier
Innate Lymphoid Cells (ILC) are tissue-resident effector lymphocytes that differ from the B and T lymphocytes subsets since they lack specific antigen receptors derived from gene rearrangements. They can be divided into two groups, cytotoxic ILC (NK cells) which are dependent on the transcription factors Eomes and T-bet and produce IFN-γ, and helper-like ILC (ILC1, ILC2, ILC3) which are dependent on T-bet, GATA-3 or RORγT and produce IFN-γ, IL-5/IL-13 or IL-17/IL-22 respectively. Although they were described recently, ILC are the subject of a large number of studies that characterize their role as one of the first effectors of the innate immune response as well as in the development of a wide number of inflammatory disorders.